BioLineRx (NASDAQ:BLRX) Lifted to Hold at StockNews.com

BioLineRx (NASDAQ:BLRXGet Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

Shares of NASDAQ:BLRX traded up $0.21 during midday trading on Thursday, reaching $1.45. 219,169 shares of the company’s stock were exchanged, compared to its average volume of 231,167. The stock has a market cap of $69.13 million, a price-to-earnings ratio of -2.59 and a beta of 2.04. The firm’s 50 day simple moving average is $1.44 and its two-hundred day simple moving average is $1.84. BioLineRx has a fifty-two week low of $1.01 and a fifty-two week high of $3.62.

BioLineRx (NASDAQ:BLRXGet Rating) last announced its quarterly earnings data on Wednesday, March 16th. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. On average, analysts expect that BioLineRx will post -0.51 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. LPL Financial LLC grew its holdings in BioLineRx by 11.4% in the fourth quarter. LPL Financial LLC now owns 73,576 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 7,500 shares during the last quarter. Advisor Group Holdings Inc. grew its holdings in BioLineRx by 105.9% in the fourth quarter. Advisor Group Holdings Inc. now owns 15,253 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 7,844 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in BioLineRx by 63.1% in the fourth quarter. Geneos Wealth Management Inc. now owns 28,950 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 11,200 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in BioLineRx in the third quarter valued at $33,000. Finally, Morgan Stanley grew its holdings in BioLineRx by 5.9% in the third quarter. Morgan Stanley now owns 240,128 shares of the biotechnology company’s stock valued at $660,000 after purchasing an additional 13,306 shares during the last quarter. Institutional investors own 5.23% of the company’s stock.

About BioLineRx (Get Rating)

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

Further Reading

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.